Short answer
Disc Medicine, Inc. (IRON) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure). Pivotal Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints.
Disc Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Pivotal Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints
- Results cover adults and adolescents with erythropoietic protoporphyria, supporting regulatory advancement
- Positive pivotal data materially strengthen bitopertin’s commercialization prospects in EPP
- Full trial results and supporting details in Exhibit 99.1
Item 8.01 · Other Events
- APOLLO Phase 3 met all primary and secondary endpoints in 183 EPP/XLP patients, materially de-risking bitopertin’s efficacy profile
- PPIX reduced 41.4% versus placebo, while monthly pain-free light exposure increased 12.2 hours, both statistically significant
- Phototoxic reactions, cumulative pain-free light exposure and patient-reported quality of life all improved versus placebo
- Dizziness affected 50% of bitopertin patients, generally mild or moderate and transient, with no adverse events above Grade 3
- NDA resubmission planned by end-2026, with FDA decision anticipated by mid-2027, creating key regulatory catalysts and execution risk
Item EX-99.1 · Exhibit EX-99.1
- APOLLO met both co-primary endpoints, reducing PPIX 41.4% versus placebo and adding 12.2 monthly pain-free light hours
- All secondary endpoints statistically significant, including fewer phototoxic reactions and greater cumulative light tolerance
- Quality-of-life measures improved significantly, with PGIC and PGIS both p<0.0001
- Safety profile supportive, dizziness most common at 50%, generally mild or moderate and transient
- NDA resubmission planned by end-2026, with FDA decision anticipated by mid-2027
Item EX-99.2 · Exhibit EX-99.2
- APOLLO met both co-primary and all secondary endpoints, materially strengthening bitopertin’s case for EPP approval
- PPIX fell 41.4% versus placebo, while month-six pain-free light exposure increased 12.2 hours
- Phototoxic reaction incidence declined 71% versus placebo, with time to prodrome improving 56 minutes
- Safety remained favorable, though dizziness affected 50% on bitopertin versus 11% on placebo
- NDA resubmission planned by end-2026, with FDA decision anticipated by mid-2027 and $2B+ US addressable market cited
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Disc Medicine, Inc. 8-K filings
Get the next IRON 8-K as it lands
Follow IRON for push alerts, or ask the research agent what this filing means.